Page 22 - Nuclear Export News Today

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer -- Richard Paulson, Recent Chief Executive Officer of Ipsen North America and Former Vice President and General Manager of Oncology at Amgen, Brings Wealth of Commercial Leadership and Global Strategic Experience -- -- Michael G. Kauffman to Remain on Board of Directors and Assume New Role as Senior Clinical Advisor-- News provided by Share this article Share this article NEWTON, Mass., May 3, 2021 ...

Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress -- Total Revenues of $23.3 Million for the First Quarter of 2021; XPOVIO® (selinexor) Net Product Sales of $21.7 Million -- -- Conditional Marketing Authorization Granted by the European Commission for NEXPOVIO® (selinexor) in Penta-Refractory Multiple Myeloma; European Decision for Expanded Multiple Myeloma Indication Expected in the Fourth Quarter of 2021 -- -- Richard Paulson Appointed Next Presi...

/PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Published: Apr 26, 2021   NEWTON, Mass., April 26, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Medicines Agency (EMA) has validated the Companys Type II Variation Marketing Authorization Application (MAA), which seeks to expand the currently authorized indication for NEXPOVIO® in the European Union to include, in combination with Velcade® (bortezomib) and...

Senior honors defenses mark end of intensive research projects Share on: Posted on Wednesday, April 7, 2021 This spring, several Westminster College senior honors scholars will publicly defend their capstone research—a culmination of nearly two years’ worth of high-level academic exploration. “While every student at Westminster experiences capstone, students in the All-College Honors Program begin working on their capstone research early in the junior year, developing and ...

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) News provided by Share this article Share this article NEWTON, Mass., March 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharms Board of Directors granted stock options to purchase an aggregate of 93,600 shares of Karyopharms common stock to 11 newly-hir...

Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress -- Commercial Launch of XPOVIO® (selinexor) In Expanded Multiple Myeloma Indication Fully Underway Following December 18, 2020 FDA Approval -- -- XPOVIO Net Product Sales of $20.2 Million for Fourth Quarter 2020 and $76.2 Million for the Year 2020; Total Revenues of $35.1 Million for the Fourth Quarter 2020 and $108.1 Million for the Year 2020 -- -- Positive CHMP Opinion for NEXPOVIO®...

Share this article Share this article NEWTON, Mass., Feb. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its partner Promedico Ltd., a member of the Neopharm Group, has received a principal approval letter from the Israeli Ministry of Health, Israels regulatory agency responsible for the approval of new medicines, granting the approval of XPOVIO® (selinexor) for the treatment...